Sign in

    Jim Birchenough

    Research Analyst at Wells Fargo

    Jim Birchenough's questions to SNSS leadership

    Jim Birchenough's questions to SNSS leadership • Q2 2017

    Question

    Jim Birchenough of Wells Fargo inquired about the SNS-062 program's dose-escalation plan, the dose needed for C481S mutation efficacy, and potential early data readouts. He also asked about the company's financial position, including its cash runway, a potential milestone payment for TAK-580, ATM facility usage, and other non-dilutive funding sources.

    Answer

    Chief Scientific Officer Judy Fox outlined the dose-escalation for SNS-062, anticipating sustained BTK inhibition around the 100-200mg cohorts. President and CEO Dan Swisher confirmed a clinical update is targeted for Q2 2018. On financials, Swisher stated the cash runway extends into Q2 2018, noted a potential multi-million-dollar milestone from Takeda for TAK-580, and mentioned other options like the PDK1 program and ATM facility to fund operations to key milestones.

    Ask Fintool Equity Research AI

    Jim Birchenough's questions to SNSS leadership • Q1 2017

    Question

    Jim Birchenough of Wells Fargo inquired about the competitive positioning of SNS-062 against programs like Arkhill's, the logistics of patient enrollment at the shared Ohio State site, the size of the patient pool there, and the company's strategy for monetizing the vosaroxin asset.

    Answer

    President and CEO Dan Swisher stated that clinical data will ultimately determine SNS-062's competitive position and noted their first-to-clinic opportunity. VP of Clinical Development Linda Neuman added that their trial is active at OSU while Arkhill's is not, providing an advantage. Regarding vosaroxin, Dan Swisher and Par Hyare, VP of Global Oncology Operations, explained they are leveraging prior European partnering interest to pursue a global partnership to fund a new trial.

    Ask Fintool Equity Research AI

    Jim Birchenough's questions to SNSS leadership • Q3 2016

    Question

    Jim Birchenough of Wells Fargo inquired about the possibility of securing a European partner for vosaroxin based on the Day 180 questions from the EMA. He also asked about the current treatment paradigm for Cys-481S mutant patients and the feasibility of a small investigator-initiated trial for SNS-062 to establish proof-of-concept.

    Answer

    President and CEO Dan Swisher stated that the company's current guidance is to finalize a partnership around the time of the CHMP opinion. Regarding the BTK inhibitor, Mr. Swisher acknowledged the growing unmet need. Linda Neuman, VP of Clinical Development, added that the Phase 1 study will enroll CLL patients, providing an early read, while the Phase 2 portion will specifically target a cohort with the Cys-481S mutation to formally establish proof-of-concept.

    Ask Fintool Equity Research AI